Updates in AML Care: Evolving ASH Guidelines for Older Adults
On the Frontlines of AML/ALLUpdates in AML Care: Evolving ASH Guidelines for Older Adults
Venetoclax and Palbociclib in AML: Exploring New Findings
On the Frontlines of AML/ALLVenetoclax and Palbociclib in AML: Exploring New Findings
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
On the Frontlines of AML/ALLAdvancing Relapse Prediction in Pediatric AML Through Genomic MRD
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Project Oncology®How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Understanding the Growing Burden of Early-Onset CRC
On the Frontlines of Colorectal CancerUnderstanding the Growing Burden of Early-Onset CRC
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerDecoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
- advertisement
- 4 questions
- 3 questions
- 4 questions
- 2 questions
- 10 questions
- 4 questions
- advertisement
Evaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
Medical Industry FeatureEvaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
Early CAR T Cell Therapy Referral: The Missing Piece in Blood Cancer Treatment
Project Oncology®Early CAR T Cell Therapy Referral: The Missing Piece in Blood Cancer Treatment
Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
Project Oncology®Harnessing the Immune Power: A Uniquely Designed PD-1 Inhibitor for Esophageal Cancer
Latest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
Medical Industry FeatureLatest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
Managing Eye-Related Adverse Events Caused by Cancer Treatments
Medical Industry FeatureManaging Eye-Related Adverse Events Caused by Cancer Treatments
- 03/19/2026
- 03/18/2026
- 03/16/2026
- 03/16/2026
- 03/16/2026
- 03/13/2026